Search

Displaying results 3931 - 3940 of 8517 in total
  1. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.

  2. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623]

  3. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. … Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.

  4. Drug

    Silver nitrate

    go.drugbank.com/drugs/DB11080
    Approved

    It is often used as a precursor to other silver-containing compounds. … It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization in PAGE gels and in scanning electron microscopy.

  5. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  6. Drug

    Indopan

    go.drugbank.com/drugs/DB01446
    ExperimentalIllicit

    It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.

  7. Drug

    Ularitide

    go.drugbank.com/drugs/DB05034
    Investigational

    When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation. … Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).

  8. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent

  9. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]

    Synonyms: -CHAIN, (231->224'), (234->227')-BIS(DISULFIDE)
  10. Drug

    Drozitumab

    go.drugbank.com/drugs/DB19106
    Investigational

    It was developed by Genentech as a drug for the treatment of cancers